ENVB News and Press, Enveric Biosciences Inc Com

2024-07-15 10:24:58 ET More on Enveric Biosciences Enveric Biosciences signs $66.5M non-binding term sheet with MindBio Therapeutics Seeking Alpha’s Quant Rating on Enveric Biosciences Historical earnings data for Enveric Biosciences Financial informat...

Aries to clinically develop and market Enveric’s patented product for radiation dermatitis Enveric Biosciences (NASDAQ: ENVB) (“Enveric”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorde...

US patent includes broad claims for treating brain neurological disorders Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric diso...

2024-07-08 17:48:26 ET More on Enveric Biosciences Enveric Biosciences signs $66.5M non-binding term sheet with MindBio Therapeutics Seeking Alpha’s Quant Rating on Enveric Biosciences Historical earnings data for Enveric Biosciences Financial informat...

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s ma...

EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically associated with psychedelic-based compounds Enveric is advancing pre-clinical development of EB-003 with a pre-IND meeting targeted for early 2025 ...

2024-06-05 07:17:36 ET More on ATAI, COMPASS Pathways, etc. ATAI: Enormous Potential Upside But No Clarity Yet Psychedelics Closer To Commercialization; Compass Far And Away The Leader COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript Biggest stock...

2024-06-04 17:32:04 ET More on psychedelic drug companies ATAI: Enormous Potential Upside But No Clarity Yet Psychedelics Closer To Commercialization; Compass Far And Away The Leader COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript Psychedelic sto...

2024-05-31 10:43:44 ET More on ATAI, COMPASS Pathways, etc. ATAI: Enormous Potential Upside But No Clarity Yet Psychedelics Closer To Commercialization; Compass Far And Away The Leader COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript Mind Medicine...

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Com...